<DOC>
	<DOCNO>NCT00161369</DOCNO>
	<brief_summary>Homocysteine ( Hcy ) asymmetric dimethylarginine ( ADMA ) recently recognize potential risk factor atherosclerosis general population , metabolism substance seem closely relate . This study investigate association substance , whether elevate serum level Hcy ADMA would relate high risk atherosclerosis cardiovascular event maintenance hemodialysis ( HD ) patient .</brief_summary>
	<brief_title>Effect Homocysteine Asymmetric Dimethylarginine Cardiovascular Events Hemodialysis Patients</brief_title>
	<detailed_description>Objective- Homocysteine ( Hcy ) asymmetric dimethylarginine ( ADMA ) recently recognize potential risk factor atherosclerosis general population , metabolism substance seem closely relate . This study investigate association substance , whether elevate serum level Hcy ADMA would relate high risk atherosclerosis cardiovascular event maintenance hemodialysis ( HD ) patient . Methods- The subject recruit day-time night-time HD patient Maruyama Hospital . The study inclusion criterion patient receive hemodialysis therapy 6 month , stable condition 70 year old . The degree atherosclerosis evaluate four index involve carotid artery intima-media thickness ( IMT ) , carotid artery plaque , percentile calcification index abdominal aortic wall ( ACI ) elongation thoracic aorta . At time , plasma Hcy ADMA measure . After initial laboratory examination evaluation degree atherosclerosis , patient follow 5 year .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>N , N-dimethylarginine</mesh_term>
	<criteria>The study inclusion criterion patient receive hemodialysis therapy 6 month , stable condition 70 year old . Any patient show sign heart failure history apparent cardiovascular disease myocardial infarction , cardiac valve disease stroke exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>homocysteine</keyword>
	<keyword>asymmetric dimethylarginine</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>cardiovascular event</keyword>
	<keyword>hemodialysis</keyword>
</DOC>